July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
A Novel Hypoxia-Regulated And Cell -Specific Gene Therapy Elicits Reduced Choroidal Neovascularization
Author Affiliations & Notes
  • Manas Ranjan Biswal
    Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, United States
    Integrative Biology program, Department of Biology, Florida Atlantic University , Boca Raton, Florida, United States
  • Howard M Prentice
    Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, United States
  • George W Smith
    Integrative Biology program, Department of Biology, Florida Atlantic University , Boca Raton, Florida, United States
  • Ping Zhu
    Department of Ophthalmology, University of Florida, Gainesville, Florida, United States
  • Tong Yao
    Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, United States
  • C Kathleen Dorey
    Department of Basic Science, Virginia Tech Carilion School of Medicine, Roanoke, Virginia, United States
  • Alfred S Lewin
    Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, United States
    Department of Ophthalmology, University of Florida, Gainesville, Florida, United States
  • Janet C Blanks
    Integrative Biology program, Department of Biology, Florida Atlantic University , Boca Raton, Florida, United States
    Center for Complex Systems and Brain Sciences, Florida Atlantic University, Boca Raton, Florida, United States
  • Footnotes
    Commercial Relationships   Manas Ranjan Biswal, None; Howard Prentice, Eye-Gen (P); George Smith, None; Ping Zhu, None; Tong Yao, None; C Kathleen Dorey, Eye-Gen (P); Alfred Lewin, None; Janet Blanks, Eye-Gen (P)
  • Footnotes
    Support  NIH grant EYO16119 (JCB), NIH Core grant P30EY014801 (ASL), Shaler Richardson Endowment (ASL), Research Priority grant from FAU (JCB), Davimos Family Endowment for Excellence in Science (JCB), American Heart Association grant 0815022E (MRB), NIH grant 1K99EY027013 [MRB] .
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3965. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Manas Ranjan Biswal, Howard M Prentice, George W Smith, Ping Zhu, Tong Yao, C Kathleen Dorey, Alfred S Lewin, Janet C Blanks; A Novel Hypoxia-Regulated And Cell -Specific Gene Therapy Elicits Reduced Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3965.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the prophylactic effectiveness of a novel retinal pigment epithelial cell (RPE) specific, hypoxia-regulated gene therapy in the mouse model of laser-induced choroidal neovascularization (CNV).

Methods : An AAV gene therapy vector comprising RPE-specific promoter and HIF-1 response elements (HRE) was designed to regulate production of human endostatin (a powerful angiostatic protein). One eye of C57BL/6J mice was subretinally injected with Regulated-RPE-specific AAV driving endostatin, or with AAV vectors constitutively expressing endostatin or GFP driven by CMV promoter as a positive and vehicle control respectively. Contralateral control eyes were subretinally injected with vehicle; laser photocoagulation induced CNV in all eyes 14 or 90 days later. The areas of CNV present 14 days later were analyzed in images obtained in vivo by spectral domain optical coherence tomography (SD-OCT) and post mortem in RPE flat mounts. Exogenous endostatin expression in RPE/choroid was assayed by quantitative RT-PCR on day 3, 7, 14, and 45 days after laser photocoagulation.

Results : Exogenous endostatin expression by the regulated vector was significantly elevated 3, 7 and 14 days following laser treatment and expression was completely off by 45 days. In both SD-OCT and confocal images of RPE flat mounts, CNV areas were 80% smaller in regulated vector eyes than in untreated control eyes (P<0.001). This inhibition of CNV was comparable to that in eyes treated with the unregulated vector constitutively expressing endostatin, emphasizing that focal delivery of endostatin is sufficient to suppress CNV.

Conclusions : These findings support the possibility of reducing development of CNV by prophylactic treatment with RPE-specific, hypoxia-regulated gene therapy delivery of anti-angiogenic agents at the moment and at the site where CNV arises. This approach would avoid any harmful effect of continuous exposure to anti-angiogenic agents.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×